Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers

Journal of Infectious Diseases

Volumn 192, Issue 5, 2005, Pages 739-748

  Mekonnen, Yared ^a   Geskus, Ronald B ^c,d   Hendriks, Jan C M ^b   Messele, Tsehaynesh ^a   Borghans, Jose ^d   Miedema, Frank ^d   Wolday, Dawit ^a   Coutinho, Roel A ^a,c,d   Dukers, Nicole H T M ^a,c,d  

^a Ethio Netherlands AIDS Research Project ENARP   (Ethiopia)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c MUNICIPAL HEALTH SERVICE   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ETHIOPIA; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDUSTRIALIZATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; SURVIVAL TIME; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE PROGRESSION; ETHIOPIA; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MARKOV CHAINS; MODELS, IMMUNOLOGICAL; SURVIVAL ANALYSIS;

EID: 23944452934     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/432545     Document Type: Article

References (48)

1. French N, Mujugira A, Nakiyingi J, Mulder D, Janoff EN, Gilks CF. Immunological and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced diseases. J Acquir Immune Defic Syndr 1999; 22:509-16.
2. Collaborative Group on AIDS Incubation and HIV-1 survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of a highly active antiretroviral therapy, a collaborative re-analysis. Lancet 2000; 355:1131-7.
3. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995; 16:187-91.
4. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1-8.
5. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000; 1:285-9.
6. Anzala OA, Nagelkerke NJ, Bwayo JJ, et al. Rapid progression of disease in Africa sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995; 171:686-9.
7. N'Galy B, Ryder RW, Bila K, et al. Human immunodeficiency virus infection among employees in an African hospital. N Engl J Med 1988; 319:1123-7.
8. Whittle H, Egboga A, Todd J, et al. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. AIDS 1992; 6:685-9.
9. Mann JM, Bila K, Colebunders RL, et al. Natural history of human immunodeficiency virus infection in Zaire. Lancet 1986; 2:707-9.
10. Crampin AC, Floyd S, Glynn JR, et al. Long-term follow-up of HIV-1-infected and HIV-1-uninfected individuals in rural Malawi. AIDS 2002; 16:1545-50.
11. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002; 16:597-603.
12. Morgan D, Whitworth J. The natural history of HIV-1 infection in Africa. Nat Med 2001; 7:143-5.
13. Urassa W, Bakari M, Sandstrom E, et al. Rate of decline of absolute number and percentages of CD4 lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. AIDS 2004; 18:433-8.
14. Phillips AN, Pezzotti P, Lepri AC, Rezza G, the Italian Seroconversion Study. CD4 lymphocyte count as a determinant of the time for HIV-1 seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study. AIDS 1994; 8:1299-305.
15. + T-lymphocyte decline in HIV-1-infected individuals: a Markov modeling approach. J Acquir Immune Defic Syndr 1991; 4:1141-7.
16. 1997 revised guidelines for performing CD4+ T cell determinations in persons infected with human immunodeficiency virus (HIV). Centers for Disease Control and Prevention. MMWR Recomm Rep 1997; 46: 1-29.
17. Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein W Jr. Patterns of T-lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr 1989; 2:63-9.
18. Phillips AN, Lee CA, Elford J, et al. Serial CD4 lymphocyte counts and the development of AIDS. Lancet 1991; 337:389-92.
19. Hendriks JC, Satten GA, van Ameijden EJ, et al. The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis. AIDS 1998; 12: 1537-44.
20. Wolday D, Tsegaye A, Messele T. Low absolute CD4 counts in Ethiopians. Ethiop Med J 2002;40(Suppl 1):11-6.
21. Pollack S, Fuad B, Etzioni A. CD4 T-lymhocytopenia without opportunistic infection in HIV-1-uninfected Ethiopian immigrants to Israel. Lancet 1993; 342:50.
22. Kalinkovich A, Weisman Z, Burstein R, Bentwich Z. Standard values of T-lymphocyte subsets in Africa. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:183-5.
23. Kassa E, Rinke de Wit TF, Hailu E, et al. Evaluation of the World Health Organization staging system for HIV-1 infection and disease in Ethiopia: association between clinical stages and laboratory markers. AIDS 1999; 13:381-9.
24. Messele T, Abdulkadir M, Fontanet AL, et al. Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin Exp Immunol 1999; 115: 443-50.
25. Rinke de Wit TF, Tsegaye A, Wolday D, et al. Primary HIV-1 subtype C infection in Ethiopia. J Acquir Immune Defic Syndr 2002; 30:463-70.
26. Hazenberg MD, Otto SA, Cohen Stuart JW, et al. Increased cell division but not thymic dysfunction rapidly affects the T cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000; 6:1036-42.
27. Tugume SB, Piwowar EM, Lutalo T, et al. Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol 1995; 2:233-5.
28. Levin A, Brubaker G, Shao JS, et al. Determination of T-lymphocyte subsets on site in rural Tanzania: results in HIV-1-infected and non-infected individuals. Int J STD AIDS 1996; 7:288-91.
29. Zekeng L, Sadjo A, Meli J, et al. T-lymphocyte subsets values among healthy Cameroonians. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:82-3.
30. Embree J, Bwayo J, Nagelkerke N, et al. Lymphocyte subsets in human immunodeficiency virus type 1-infected and uninfected children in Nairobi. Pediatr Infect Dis J 2001; 20:397-403.
31. Mekonnen Y, Sanders E, Aklilu M, et al. Evidence of changes in sexual behaviors among male factory workers in Ethiopia. AIDS 2003; 17: 223-31.
32. Hendriks JC, Satten GA, Longini IM, et al. Use of immunological markers and continuous-time Markov models to estimate progression of HIV-1 infection in homosexual men. AIDS 1996; 10:649-56.
33. The WHO International Collaborating Group for the Study of the WHO Staging System. Proposed "World Health Organization staging system for HIV-1 infection and disease": preliminary testing by an international collaborative cross-sectional study. AIDS 1993; 7:711-8.
34. Sypsa V, Touloumi G, Kenward M, Karafoulidou A, Hatzakis A. Comparison of smoothing techniques for CD4 data in a Markov model with states defined by CD4: an example on the estimation of the HIV-1 incubation time distribution. Stat Med 2001; 20:3667-76.
35. Satten GA, Longini, IM. Markov chains with measurement error: estimating the "true" course of a marker of the progression of human immunodeficiency virus disease (with discussion). Appl Stat 1996; 45: 275-309.
36. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comp Graph Stat 1996; 5:299-314. Available at: http://www.r -project.org. Accessed 18 July 2005.
37. Taylor IMG, Cumberland WG, Sy JP. A stochastic model for analysis of longitudinal AIDS data. J Am Stat Assoc 1994; 89:727-36.
38. Multicohort Analysis Project Workshop. Immunological markers of AIDS progression: consistency across five HIV-1-infected cohorts, part 1. AIDS 1994; 7:911-21.
39. Pehrson P, Lindback S, Lidman C, Gaines H, Giesecke J. Longer survival after HIV-1 infection for injecting drug users than for homosexual men: implications for immunology. AIDS 1997; 11:1007-12.
40. Koblin BA, van Benthem BH, Buchbinder SP, et al. Long-term after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1987-1995. Am J Epidemiol 1999; 150:1026-30.
41. Mekonnen Y, Dukers NH, Sanders E, et al. Simple markers for initiating antiretroviral therapy among HIV-1-infected Ethiopians. AIDS 2003; 17:815-9.
42. Schechter MT, Le N, Craib KJ, Le TN, O'Shaughnessy MV, Montaner JS. Use of the Markov model to estimate the waiting times in a modified WHO staging system for HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:474-9.
43. Longini IM, Clark WS. Statistical analysis of the stages of HIV-1 infection using Markov model. Stat Med 1989; 8:831-43.
44. Munoz A, Carey V, Saah AI, et al. Predictors of decline in CD4 lymphocytes in a cohort of homosexual men infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1988; 1:396-404.
45. Easterbrook PJ, Emami I, Gazzard B. Rate of CD4 cell decline and prediction of survival in zidovudine treated patients. AIDS 1993; 7:959-67.
46. Abebe A, Demissie D, Goudsmit J, et al. HIV-1 subtype C syncytium-and non-syncytium-Ethiopian patients with AIDS. AIDS 1999; 13:1305-11.
47. Fagnoni FF, Vescovini R, Passeri G, et al. Shortage of circulating naive CD8+ T cells provides new insights on immunodeficiency in aging. Blood 2000; 95:2860-8.
48. Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viraemia. Immunity 2003; 18:441-52.